Wealth Enhancement Advisory Services LLC Sells 77 Shares of Insulet Co. (NASDAQ:PODD)

Wealth Enhancement Advisory Services LLC decreased its stake in shares of Insulet Co. (NASDAQ:PODD) by 3.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,274 shares of the medical instruments supplier’s stock after selling 77 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Insulet were worth $529,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock worth $1,405,328,000 after purchasing an additional 169,506 shares in the last quarter. Baillie Gifford & Co. raised its holdings in Insulet by 30.8% in the second quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after buying an additional 443,783 shares during the last quarter. Clearbridge Investments LLC lifted its stake in shares of Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after buying an additional 75,526 shares in the last quarter. William Blair Investment Management LLC grew its holdings in shares of Insulet by 3.7% during the first quarter. William Blair Investment Management LLC now owns 952,268 shares of the medical instruments supplier’s stock valued at $163,219,000 after buying an additional 33,579 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Insulet by 18.7% during the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock valued at $178,728,000 after acquiring an additional 139,246 shares in the last quarter.

Analyst Ratings Changes

Several brokerages have commented on PODD. BTIG Research increased their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday. Barclays lifted their price objective on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Canaccord Genuity Group upped their target price on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. UBS Group lifted their price target on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Finally, Sanford C. Bernstein initiated coverage on shares of Insulet in a research report on Wednesday. They set an “outperform” rating and a $300.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average price target of $246.80.

Insulet Price Performance

NASDAQ PODD opened at $268.00 on Friday. The stock has a market cap of $18.79 billion, a price-to-earnings ratio of 48.73, a PEG ratio of 4.47 and a beta of 1.22. Insulet Co. has a 12 month low of $151.56 and a 12 month high of $275.52. The company’s 50 day moving average is $232.01 and its two-hundred day moving average is $203.96. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The firm had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. During the same period in the prior year, the company posted $0.38 EPS. The company’s quarterly revenue was up 23.2% on a year-over-year basis. As a group, research analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.